Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.

You may also be interested in...



ThromboGenics Takes Its Time On Solo Launch Of Eye Drug Jetrea

Having taken a conservative approach to its first commercial launch, ThromboGenics plans to roll out newly approved eye drug Jetrea (ocriplasmin) in January 2013. Company is now recruiting a sales force to target retinal specialists, who are already well aware of the new drug.

Jetrea Launch Plans Include 30 Sales Reps, 15 Reimbursement Specialists

“Confident” ThromboGenics CEO De Haes tells investors, “we have already hired our senior marketing and sales managers and regional sales managers” following an advisory committee vote that went even better than the firm had expected.

Eyeing Solo U.S. Debut, EU Biotech ThromboGenics Preps Ocriplasmin For Launch

Small European biotechs usually build their business in their home region first, and later look to the US for growth. Belgium's ThromboGenics is doing the opposite; it aims to launch its lead product initially in the US, and will tackle Europe after partner and market leader Alcon paves the way.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel